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The V3 domain plays a central role in the biology of the HIV-1 Env glycoprotein gp120 as a dominant target for neutralizing
antibodies for some HIV-1 isolates, and as a major determinant in the switch from the nonsyncytium-inducing (NSI) to the
syncytium-inducing (SI) form of HIV-1 that is associated with accelerated disease progression. Basic amino acid substitutions
are known to play an important role in the SI phenotype. We have used the presence of basic amino acid substitutions in
V3 sequences to divide sequences in a large data base into SI-like and NSI-like. We found significant differences in features
of sequence variability between these two groups of sequences. Of the thirty-six most frequent substitutions in V3, twenty
appear disproportionately among either the SI-like sequences or the NSI-like sequences. The fourteen favored substitutions
among the SI-like sequences account for 50% of the twofold increased variability seen in this group. In addition, we found
a linked change within the CD4-binding domain of gp120 downstream of V3. These differences are interpreted in the context
of structure, function, and selective pressure. An understanding of these patterns of sequence variability offers the possibility
of designing a degenerate SI-specific V3 immunogen to use as a therapeutic vaccine with the hope of slowing or preventing
the appearance of SI variants. q 1997 Academic Press
INTRODUCTION tains virus replication in vivo is not known for either type
of virus.
Approximately 50% of patients infected with HIV-1 sub-
The characterization of two important molecular deter-type B evolve a variant, the appearance of which corre-
minants involved in the NSI/SI phenotype support thelates with an accelerated loss of CD4/ T cells (Asjo et
model of two virus states. First, sequence changes withinal., 1986; Cheng-Mayer et al., 1988b; Koot et al., 1993;
the V3 region of the gp120 Env glycoprotein are majorSchellekens et al., 1992; Tersmette et al., 1989a,b). How-
determinants of the NSI/SI phenotype as well as macro-ever, the selective pressures that give rise to this variant
phage-tropism/MT-2 cell-tropism (reviewed in Seillier-from its parental virus are not known. Because of the
Moiseiwitsch et al., 1994). Second, while NSI and SI vari-strong correlation between the presence of virus capable
ants both use the CD4 molecule as a receptor, they useof causing syncytium in MT-2 cells (syncytium-inducing
different members of the chemokine receptor family asor SI) and a patient course characterized by an acceler-
coreceptors, primarily CCR-5 for the NSI variants andated CD4/ T cell loss, MT-2 cell-tropism with the ability
CXCR-4 for the SI variants (reviewed in Fauci, 1996).to induce syncytia has become an experimental surro-
These observations suggest that V3 determines thegate for studying these in vivo variants. This paradigm
choice of coreceptor, and there is direct evidence for thishas given rise to a model of two virus states to explain
(Trkola et al., 1996; Wu et al., 1996).both the parental and variant forms of virus. The parental
The most consistent correlation between the SI pheno-strain, which is nonsynyctium inducing or NSI, is able to
type and changes in the Env sequence has been theinfect macrophages and primary T cells and is the form
presence of basic amino acid substitutions within the 35of virus most often transmitted (McNearney et al., 1992;
amino acid long V3 loop region (reviewed in Seillier-Schuitemaker et al., 1992; Schuitemaker et al., 1991; Van’t
Moiseiwitsch et al., 1994; see also Cornelissen et al.,Wout et al., 1994; Zhu et al., 1993). The SI variant also
1995; Distler et al., 1995; Fouchier et al., 1995b). However,infects primary T cells and, by definition, MT-2 cells, and
the use of recombinant viruses or selection for tropismevolves de novo in individual patients (reviewed in Mie-
in transformed T cell lines has clearly demonstrated thatdema et al., 1994). The nature of the cell type that sus-
the ability to grow in a transformed T cell line is not
solely determined by the presence of basic amino acids
1 Present address: Box 2601, Department of Experimental Surgery, in V3 (Boyd et al., 1993; Chesebro et al., 1996). Further-Duke University Medical School, Durham, NC 27710.
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utilize different or multiple chemokine receptors (Choe The remaining 110 V3 sequences in the data set were
obtained predominantly from the HIV-1 sequence dataet al., 1996; Deng et al., 1996; Simmons et al., 1996),
viruses that have complex and differing tropisms for pri- base (Myers et al., 1996). Eighty-three of these se-
quences, including 10 pairs of in vivo-derived V3 se-mary cells and transformed T cell lines (Chesebro et al.,
1996), and viruses that are T cell line-tropic but do not quences, have also been previously described (Milich et
al., 1993). For the present study, 27 new V3 sequencescause syncytia (Chowdhury et al., 1995; Yoshimura et al.,
1996). Nonetheless, the correlation between basic amino were added to the data set. These sequences were deter-
mined for isolates from 27 individuals and most representacid substitutions in V3 and the acquisition of growth
and syncytia induction in MT-2 cells remains a useful in vivo-derived sequences. In all cases only one se-
quence for isolates from a single patient was included.model for the description of most of the variant viruses
that evolve around the time of rapid disease progression. The viruses were isolated predominantly from the blood
although one from brain and one from lymph node wereA change from the NSI to the SI state results in both
biological and physical changes in gp120. NSI viruses included. In cases where HIV was known to be transmit-
ted from one specific individual to another, the isolateare fairly resistant to antibody-mediated neutralization
while SI variants are more sensitive to neutralization from only one person was used. All sequences used in
this analysis represent viruses from North America or(Bou-Habib et al., 1994; Cheng-Mayer et al., 1988a; Sulli-
van et al., 1995), and much of the neutralizing antibody Europe and therefore the conclusions reached apply most
directly to subtype B HIV-1. A compilation of the V3 aminois directed at the V3 loop (Javaherian et al., 1989; Profy
et al., 1990; Vancott et al., 1995; Vogel et al., 1994). This acid sequences that comprise the entire data set is avail-
able upon request. All forty-six Env sequences used toheightened sensitivity to neutralization is correlated with
enhanced antibody binding and accessibility to prote- correlate patterns of sequence variability in V3 and amino
acid substitutions throughout Env were obtained from theases in V3 of gp120 Env from the SI viruses (Ebenbichler
et al., 1993). These observations suggest that in the SI HIV-1 sequence data base (Myers et al., 1996).
In all discussions of V3 the N-terminal cysteine is re-state V3 is more accessible and therefore a target for
neutralizing antibodies. ferred to as position 1 and amino acids are numbered
consecutively through the C-terminal cysteine which isThe V3 region from SI variants has increased sequence
variability in addition to the basic amino acid substitutions numbered 35. Reference to residues outside of V3 is
made using the numbering for the HIV-1MN Env aminowhen compared to NSI isolates (Chesebro et al., 1992;
McNearney et al., 1992; Milich et al., 1993). In this manu- acid sequence (Myers et al., 1996); Position 1 of the V3
loop corresponds to position 301 in the HIV-1MN Envscript we account for approximately one-half of the in-
creased variability as being specific substitutions that are amino acid sequence. Inferences concerning codon us-
age were based on assessing the predominant nucleo-linked to the presence of the basic substitutions. In addi-
tion, we confirm and extend a previous observation (Car- tide sequence in the HIV-1 sequence data base (Myers
et al., 1996).rillo and Ratner, 1996) that indicates a change in the CD4
binding domain, within the C4 region of Env, is linked to
the changes that appear in V3 of the SI variants. One Quantitation of V3 sequence variability
goal of this effort is to define a degenerate V3 peptide
antigen that would include those determinants that define The data set of V3 sequences was first divided into
two groups of sequences. The criteria for making thisthe SI variants with the hope of generating a therapeutic
vaccine protective against their evolution. division were the presence of one or more basic amino
acid substitutions at positions 11, 13, 19, 23, 24, and 32
and a change at position 25 away from an acidic aminoMATERIALS AND METHODS
acid. V3 sequences having these features are considered
Source of V3 and Env sequences
to be SI-like (Milich et al., 1993), while those that do not
have these features are considered to be NSI-like. AThe 248 V3 sequences used in this study were se-
lected from the data set published by LaRosa et al. (1990, consensus sequence was then determined for each
group of sequences. Sequence variability within the two1991a,b) and from the HIV-1 sequence data base (Myers
et al., 1996). The 138 unique sequences from the LaRosa groups of sequences was calculated as follows. First,
the number of each substitution at each position relativedata set represent a subset of V3 sequence data set
previously described (Milich et al., 1993). Identical se- to the consensus sequence was tallied for each group
of sequences (Fig. 1), then that number was divided byquences from this data set were used only once, and
only V3 sequences that are 35 amino acids long were 135 for the group representing NSI-like sequences or
113 for the sequences representing SI-like sequencesincluded in the analysis. Sequences with a QR or RG
insert between I14 and G15 of the LaRosa consensus (135 and 113 represent the total number of V3 sequences
in each group, respectively) and then multiplied by 100sequence, and V3 sequences with other unusual inser-
tions or deletions were not included. to give percentage (Table 1).
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A statistical test was designed to assess the the viral sequences used in this analysis the phenotype
of the virus has not been directly tested. However, thedistribution of substitutions in the SI-like
and the NSI-like sequence sets same criteria that were used here to derive the two se-
quence groups were found previously to correlate with
For the purpose of this analysis, P1 is defined as the differences among a smaller set of viruses with known
fraction of the SI-like sequences that exhibit a specific
phenotypes (Milich et al., 1993). Because of the strong
substitution at a specific position. P2 is defined as the correlation between the presence or absence of basic
fraction of NSI-like sequences that exhibit a specific sub-
amino acids in V3 and the virus state, and the similarity
stitution at that position. Based on our previous analysis
between macrophage-tropic and NSI viruses, and T-cell-
we noted that on average the SI-like sequences contain
line-tropic and SI viruses, we refer to these two groups
twice as many sequence substitutions as the NSI-like
of sequences as being NSI-like and SI-like.
sequences when compared to the consensus V3 se-
In order to determine if other features of amino acid
quence (Milich et al., 1993). This allows us to form the
sequence variability exist within V3 that differ between
null hypothesis: H0 : P1  2P2 or equivalently H0 : P1 0 the two virus states, we compared directly the frequency
2P2  0. of different amino acid substitutions at specific positions
Estimates of the quantities for the data in hand are:
within the two groups of sequences. The percentage of
Pˆ1 SI/113 and Pˆ2 NSI/135, and then suitably adjusted sequence variability represented by a particular amino
for continuity.
acid substitution was calculated for each position based
A chi-square test was conducted based on the statistic
on a total of 135 NSI-like sequences and 113 SI-like
Z2, where Z is defined as: (Pˆ1 0 2Pˆ2)2/[{Pˆ1(1 0 Pˆ1)/113} / sequences. Only amino acid substitutions that appeared
{4 * Pˆ2(1 0 Pˆ2)/135}]1/2. in at least 5% of the sequences within a group were
Under the null hypothesis the statistic has a chi square
considered.
distribution with one degree of freedom. P values from
The results of this analysis are summarized in Table
this test are found in Table 1.
1. Listed for the relevant positions are the consensus
Inhomogeneity of the sequence distribution at position
amino acid and the significant amino acid changes.
440 when comparing the SI-like and the NSI-like se-
Also shown is the percentage of sequence variability
quences was determined using Fisher’s Exact Test
represented by each amino acid change. Amino acid
(Mehta and Patel, 1983).
substitutions in V3 fall into two categories: (i) sequence
changes that appear in both groups of sequences and
RESULTS
are not correlated with virus state (nondistinguishing
sequence changes); and (ii) sequence changes thatPrevious work has shown that arginine and lysine sub-
stitutions at specific positions in V3, a change away from correlate with virus state and can distinguish between
the NSI-like and SI-like groups of sequences (distin-an acidic amino acid at position 25, and the presence of
additional sequence heterogeneity distinguish SI from guishing sequence changes). Since there is twice as
much sequence variability among SI viruses comparedNSI variants of HIV-1 (Milich et al., 1993, and references
therein). We have now extended this sequence analysis to NSI viruses (Chesebro et al., 1992; Milich et al.,
1993) a nondistinguishing substitution would be ex-to look for other specific amino acid substitutions that
correlate with virus state. The sequence data base used pected to appear on average twice as often among the
SI viruses relative to the NSI viruses. Distinguishingin this analysis was derived from a total of 248 indepen-
dent V3 sequences published in the HIV-1 sequence data substitutions were considered as those that varied
from this expected 2 to 1 bias.base (Myers et al., 1996) and the LaRosa data set (La-
Rosa et al., 1990, 1991a,b). A large subset of these se-
quences was used in the earlier study of V3 sequence Amino acid substitutions within V3 that do not
variability (Milich et al., 1993). V3 sequences that have distinguish virus state
been added to the data set are described under Materi-
als and Methods. The starting point for our analysis was Sixteen of the thirty-six identified substitutions did not
distinguish between the virus states but were foundto divide sequences in the data set into two groups repre-
sentative of macrophage-tropic/NSI and T-cell-line- within V3 sequences from both groups of sequences
(Table 1). Present among the nondistinguishing se-tropic/SI viruses using the presence of nonconservative
basic amino acid substitutions at positions 11, 13, 19, quence changes are seven amino acid substitutions, T2I,
K10R, S/R11G, R18K, T22A, D29N, and H34Y, that each23, 24, and/or 32, and a change at position 25 within
the V3 sequence as parameters (Milich et al., 1993). A comprise more than 50% of the total variability at those
positions (Fig. 1). This apparent constraint on the variabil-consensus sequence was derived for each group and
the total sequence variability in the two groups is shown ity that is tolerated at these positions coupled with the
fact that these substitutions are common to both NSI-in Fig. 1. Features of sequence heterogeneity within each
group of V3 sequences were then analyzed. For most of like and SI-like sequences suggest that these seven po-
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FIG. 1. Sequence variability associated with SI-like and NSI-like sequences. Two consensus sequences were derived from a data set containing
248 published V3 sequences as described under Materials and Methods. (A) The NSI-like consensus sequence was derived from 135 V3 sequences
that have a glutamic acid or aspartic acid at position 25 or an uncharged amino acid at position 25 and no basic amino acid substitutions at
positions 11, 13, 19, 23, 24, or 32. (B) The SI-like consensus sequence was derived from 113 V3 sequences. V3 sequences in this group have an
arginine or lysine substitution at either position 25 or 11 or an uncharged amino acid at position 25 and at least one basic amino acid substitution
at positions that include 11, 13, 19, 23, 24, and 32. Listed below each consensus sequence are the amino acid substitutions at each position and
the number of V3 sequences containing these substitutions. Bold numbers represent the amino acid position within the consensus sequence.
sitions may be associated with highly conserved struc- considering all of the substitutions at these positions,
making it likely that each of these substitutions is parttural features of the V3 loop. This argument is even
stronger for those positions that show virtually no vari- of the SI-specific phenomenon; however, larger data sets
will be needed to establish statistical significance. Theability (C1, R3, P4, A33, and C35; Fig. 1).
high counts associated with the T22A substitution contri-
butes to the significance of its deviation from the ex-Amino acid substitutions within V3 that distinguish
pected 2:1 ratio even though it is a common substitutionNSI-like and SI-like sequences
in both the SI-like and the NSI-like sequence pools.
Four substitutions strongly deviated from the expected
2 to 1 ratio of the total variability and were associated Impact of sequence variability on potential N-linked
with NSI-like sequences: N5S, H13N, H13P, and E25D glycosylation sites
(Table 1). Two other substitutions showed an inverted
ratio in that they were twice as abundant in the NSI-like The consensus V3 sequence encodes two potential
N-linked glycosylation sites: one spans the N-terminalsequence pool compared to the SI-like sequence pool
but due to low counts had less significant P values: E25A cysteine at the base of the loop (NCT) and the other is
at position 6 (NNT). Both of these sites have been shownand I27T. Several substitutions occurred predominately
in the SI-like sequence pool and had very small P values: to be utilized as glycosylation sites in the context of an
SI-derived gp120 expressed in a heterologous systemR9K, H13Y, A19V, F20V, Y21V, T23A, and G24E. This anal-
ysis shows that at these positions certain substitutions (Leonard et al., 1990). Glycosylation at position 6 has
been shown to decrease the sensitivity of neutralizationare strongly associated with the presence or absence of
the basic amino acid substitutions that correlate with by antibodies directed at the V3 loop (Back et al., 1994;
Schonning et al., 1996). The first site (NCT) is disruptedvirus state.
One feature of the test statistic is that low counts in- approximately 10% of the time in both the NSI-like and
the SI-like sequences by a T2I substitution. The secondcrease the variance and therefore decrease the signifi-
cance; conversely, higher counts reduce the variance position (N6) is highly conserved in the NSI-like se-
quences but shows increased sequence variability in theand increase the significance. Several examples of this
can be seen in Table 1. There is a set of sequences that SI-like sequences (Fig. 1). Only one of the substitutions
we have characterized has the potential to create a newappear either exclusively or almost exclusively in the
SI-like sequence pool but due to low counts have only glycosylation site. The R9S substitution that occurs pre-
dominately in the SI-like sequences would create a po-marginal P values: N7Y, R9S, F20Y, Y21H, G24T, G24D,
and I27V. Positions 20, 21, and 24 show dramatic in- tential glycosylation site at N7, although it is not known
if such a site is utilized in these variants. The new glyco-creases in variability in the SI-like sequence pool when
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TABLE 1
Amino Acid Substitutions within V3 That Distinguish Virus State
Nondistinguishingc SI-liked NSI-likee
Positiona Consensusb (% Sequence variability, SI-like/NSI-like)g P valuef
2 T I 0.111(9/8)
5 N S 0.0002(4/15)
7 N Y 0.072(8/0.7)
9 R K 0.017(13/1)
9 R S 0.119(7/0.7)
10 K R 0.122(25/18)
11 R/S G 0.349(36/21)
13 H T 0.241(18/5)
13 H S 0.510(12/4)
13 H Y 0.015(7/0)
13 H N 0.0001(3/18)
13 H P 0.0001(2/15)
14 I M (10/8) 0.157
18 R K 0.153(5/7)
19 A V 0.0001(19/0)
20 F I 0.510(12/4)
20 F L 0.951(9/4)
20 F W 0.805(6/3)
20 F V 0.0001(18/0)
20 F Y 0.050(5/0)
21 Y H 0.027(6/0)
21 Y V 0.015(7/0)
22 T A 0.0001(35/46)
23 T A 0.0006(12/0)
24 G E 0.0001(15/0)
24 G T 0.050(5/0)
24 G D 0.050(5/0)
25 K/E Q 0.614(22/9)
25 K/E N 0.694(5/1)
25 K/E G 0.923(5/2)
25 K/E D 0.0001(1/34)
25 K/E A 0.037(4/7)
27 I V 0.119(7/0.7)
27 I T 0.036(4/8)
29 D N 0.130(15/12)
34 H Y 0.322(7/5)
a Position within the V3 loop with the N-terminal cysteine numbered 1.
b Consensus amino acid at the indicated position. When more than one consensus amino acid is given this indicates that the SI-like consensus
amino acid is different than the NSI-like consensus amino acid. The SI-like consensus amino acid is given first in these instances.
c Nondistinguishing amino acid substitutions, substitutions that appear in both sequence data sets and do not deviate significantly from the
expected 2:1 ratio of overall sequence variability between the two data sets.
d Substitutions that appear predominately in the SI-like sequence data set.
e Substitutions that appear predominately in the NSI-like sequence data set.
f P values were determined as described under Materials and Methods.
g The numbers presented in parenthesis represent the frequency as a percentage that the indicated substitution appears in the SI-like sequence
data set versus its frequency in the NSI-like data set.
the entire Env sequence. We found that among 26 Envsylation site usually appears with the position 6 site in-
sequences with NSI-like V3 loops, 19 contained an argi-tact, creating overlapping glycosylation signals.
nine or lysine at position 440 (HIV-1MN numbering; Myers
et al., 1996) in the CD4 binding domain of the C4 regionAn amino acid change in the CD4 binding domain that
(Fig. 2A). When we examined Env sequences with SI-likeis associated with SI-like sequences
V3 loops we found that of 20 sequences analyzed, 12
In order to identify amino acids elsewhere in Env that had either a glutamic acid or serine substitution at this
may be linked to the patterns of sequence variability in same position (Fig. 2B). The lack of homogeneity be-
tween the sequence patterns of the SI-like and NSI-likeV3 that are associated with virus tropism, we examined
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guish between macrophage-tropic/NSI and T-cell-line-
tropic/SI viruses.
DISCUSSION
V3 variation and vaccine design
The V3 loop has been identified as a primary target
of neutralizing antibodies in laboratory-adapted and SI
strains of HIV-1 (Javaherian et al., 1989; Profy et al., 1990;
Vancott et al., 1995; Vogel et al., 1994). The potential
benefit of using V3 as a vaccine target was demonstrated
through the use of an anti-V3 monoclonal antibody to
block or lower infection of an experimental animal with
a culture-adapted strain of HIV-1 (Conley et al., 1996;
Emini et al., 1992).
Peptide immunogens representing the V3 sequence
have progressed to human trials (see for example Gorse
et al., 1996; Rubinstein et al., 1995). These strategies
have been successful in eliciting neutralizing antibodies.
In an extension of this approach, complex mixtures of
V3 peptides have also been explored (‘‘mixotopes’’; see
Estaquier et al., 1994; Resnick et al., 1995). Knowledge
of the underlying patterns of V3 variability should allow
for the improved design of such complex immunogens.
To this end we have attempted to understand the pat-
terns of amino acid substitutions within V3 in NSI and SI
virus variants as part of a strategy to make an SI-specific
immunogen. In this strategy patients infected with NSI
variants would be immunized with sequence constella-
tions of V3 that are SI-specific in the hope of eliminating
FIG. 2. Linkage between V3 and a downstream amino acid in C4. A or delaying the subsequent appearance of the SI variant.
total of forty-six Env sequences from the HIV-1 data base (see Materials Such an immunogen would consist of the basic substitu-
and Methods) was divided into two groups representing NSI-like (A)
tions described previously (S11R, H13R, A19R/K, T23R,and SI-like (B) viruses according to the pattern of basic amino acid
G24R/K, E25R/K, Q32R/K; Milich et al., 1993) and the 14substitutions in V3 as described in the legend to Fig. 1. In some of the
cases the sequence used was derived from an infectious clone of a substitutions found predominantly in the SI-like pool of
virus with a known phenotype. Shown are the amino acids at the sequences (Fig. 3; N7Y, R9K/S, H13Y, A19V, F20V/Y,
positions in V3 associated with virus tropism and the corresponding Y21H/V, T23A, G24E/T/D, and I27V). In addition, a subset
amino acid at position 440 (HIV-1MN numbering; Myers et al., 1996) in of the nondiscriminating substitutions are found morethe CD4 binding domain of C4. SI-like and NSI-like viruses are repre-
frequently in the SI-like sequences and could be includedsented by 20 and 26 Env sequences, respectively. Listed in parentheses
is the number of Env sequences that contain the sequence pattern in this mix (S11G, H13T/S, F20I/L/W, and E25G/Q/N). The
shown. substitutions associated with the SI-like sequence pool
account for approximately one-half of the increased vari-
ability in this pool; including the SI-biased substitutions
groups at this position is statistically significant (P value at positions 11, 13, 20, and 25 accounts for three-fourths
of 4 1 1004 using Fischer’s Exact Test). Furthermore, the of the increased variability in V3. An important first step
presence of serine or glutamic acid at position 440 in evaluating this therapeutic vaccine strategy will be to
among the sequences with an SI-like V3 loop appeared make such a complex immunogen and determine
to be linked to the presence of arginine at position 11 in whether it can elicit an antibody response active against
V3 (Fig. 2B). Of 14 sequences with arginine at position a spectrum of primary SI isolates.
11 in V3, 10 of these had serine or glutamic acid at
position 440. In contrast, only two of six sequences had a NSI to SI switch
serine substitution at position 440 and none had glutamic
acid when arginine was not present at position 11. These We have identified 14 substitutions, in addition to the
previously described basic substitutions, that appearresults suggest that in addition to the identity of amino
acids in V3 the identity of the amino acid at position 440 predominately in the SI-like sequences. Some of the new
SI-specific substitutions are in positions that for the mostwithin the CD4 binding domain can be used to distin-
AID VY 8821 / 6a51$$$243 11-10-97 12:02:15 vira AP: VY
114 MILICH, MARGOLIN, AND SWANSTROM
FIG. 3. Summary of sequence variability in V3. The consensus sequence is shown with position numbering. The nonconservative basic amino
acid substitutions are shown as previously identified. The nondistinguishing substitutions, those associated with the SI-like sequences, and those
associated with the NSI-like sequences are shown and are described in the text. Those substitutions that are underlined are overrepresented in
the SI-like sequences compared to the NSI-like sequences as described in the text.
part have not previously been implicated in being in- is also likely to contribute to the complexity of the pat-
terns of sequence variability in V3.volved in the SI switch (N7Y, R9K, F20V/Y, Y21H/V, I27V),
while other SI-specific substitutions occur at positions
that also accommodate basic substitutions and appear Sequence variability and structure
as frequently or more frequently than the basic substitu-
tions (A19V, T23A, G24E/D/T). A role for F20Y in contribut- The importance of structure as a determinant of pat-
terns of sequence variability can be inferred by the non-ing to the SI phenotype has recently been demonstrated
using a recombinant virus (Chesebro et al., 1996). equivalence of substitutions at certain positions. As one
example, threonine appears in four positions in the con-Position 13 appears to play a central role in V3 variabil-
ity, although the nature of that role is unknown. This sensus V3 sequence and each position displays a dis-
tinctive pattern of substitutions. T8 is almost invariant inposition is the only one that has substitutions that are in
each of the three categories: nondistinguishing (H13T, the NSI-like sequences, while it shows increased vari-
ability in the SI-like sequences; T2 has one substitution,H13S), SI-like (H13Y), and NSI-like (H13N and H13P).
Changing a codon from histidine to serine or threonine isoleucine, in both sequence groups; T22 has another
substitution, alanine, in both sequence groups; and T23requires two nucleotide changes, with proline being a
likely intermediate in this pathway. The absence of pro- has an alanine substitution as an SI-specific substitution.
While patterns like this one and others are for now curi-line from the nondistinguishing group while its precursor
(histidine) and further variants (serine and threonine) are osities, they do point to underlying subtleties in the struc-
ture and interactions with other amino acids that mustin this group suggests that in most V3 backgrounds 13P
fixes V3 in an NSI state. A role for position 13 in contribut- be driving them.
The structure of a portion of the V3 loop has beening to both the NSI and SI phenotypes has been shown
using recombinant viruses (Chesebro et al., 1996). determined as a peptide bound to an anti-V3 antibody
(Ghiara et al., 1994). In that structure only V3 residuesThese patterns of substitutions do not by themselves
provide an answer to the nature of the SI switch, and in H13 through T22 are resolved (Fig. 4). The major feature
of structure in V3 is the tip of the loop which makes anfact only a fraction of these substitutions are unique to
either data set and none is present as a unique change irregular S-shaped turn. The highly conserved residues
G15, P16, G17, and R18 represent the most importantin all of the sequences in either data set. The fact that
the changes are to a large extent specific suggests that residues in forming that turn, and features of backbone
bond angles and hydrogen bonding seen in the structurethe SI state of Env is a specific structure in some way
distinct from the NSI state. Several approaches have provide explanations for the importance of these resi-
dues (Ghiara et al., 1994). Furthermore, important fea-shown that V3 is more exposed in SI variants compared
to NSI variants (Ebenbichler et al., 1993), supporting the tures of this structure are seen in V3 peptides bound to
two different neutralizing monoclonal antibodies, stronglyidea that these changes lead to a different structural
context for V3. In this more exposed state V3 may be a supporting the biological relevance of the structure (Rini
et al., 1993; Ghiara et al., 1994).more significant target for neutralization, and some of the
variability in the SI state may be attributable to humoral Analysis of the structure suggests two potential pairs
of side chain interactions among these residues, andselection. Given the variability in the rest of the Env se-
quence it is also possible that the specific changes re- these potential interactions are supported by the substi-
tution patterns at these positions. One is H13 with Y21,quired to acquire the SI phenotype may vary depending
on features of structure elsewhere in Env. Finally, the with the side chains oriented toward each other and
approximately 4.5 to 5 A˚ apart. Although this distance iscomplex nature of coreceptor choice and its impact on
the variability seen in primary cell and cell line tropism actually too great to indicate an interaction, this portion of
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FIG. 4. The structure of V3 modeled with an A19V substitution (H13, I14, G15, P16, G17, R18, A19V, F20, Y21, T22) is shown as described in
(Ghiara et al., 1994). The figure was generated using the computer program Ribbons. The A19V substitution was introduced into the graphical
representation of the structure using the computer program O.
the structure is less well ordered in the crystal structure these V3 sequences had both substitutions. Although the
number of sequences is small, the presence of threeraising the possibility that a small reorientation of the
side chains would allow for a favorable interaction. In sequences containing both substitutions is more fre-
quent than would be expected given a pool of 113 se-the SI-like sequences these amino acids substitute for
each other (H13Y and Y21H), suggesting that there might quences.
The other potential interaction is between the sidealso be an interaction if these substitutions occur to-
gether. In the SI-like V3 sequences there were seven chains at positions A19 and F20. Each of these positions
is found substituted with valine approximately 20% of theexamples of H13Y and six examples of Y21H. Three of
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time among the SI-like sequences but in this data set Also, changes in a variable region upstream of V3 have
been suggested to have at least a transient value inthese valine substitutions are not found together. When
valine appears at position 20 an alanine is present at predicting progression to SI (Cornelissen et al., 1995;
Fouchier et al., 1995a; Groenink et al., 1993; Palmer etposition 19 in 17 of the 20 sequences. In contrast, when
valine is present at position 19, phenylalanine, tyrosine, al., 1996).
As an alternative approach we aligned full-length Envleucine, and tryptophan all appear with approximately
equal frequency at position 20 but not valine. A19 and sequences and searched for changes elsewhere in Env
that correlated with the presence or absence of basicF20 are between 4.5 and 5 A˚ apart and thus unlikely to
interact. However, a valine at position 19 would allow a amino acid substitutions in V3 (Seillier-Moiseiwitsch et
al., 1994). We found a potential linkage between V3 andclose interaction (on the order of 3.1 A˚; Fig. 4) with a
position 20 phenylalanine, tyrosine, leucine, or trypto- position 440 in the conserved motif YAPPIR. A basic resi-
due is usually present at position 440 when V3 is NSI-phan. Thus a substitution to valine at position 19 may
create a new interaction that could be maintained with like, and this changes to glutamic acid or serine in the
SI-like sequences, especially when arginine appears ata limited set of substitutions at position 20. However, if
position 20 is substituted with valine there would be no position 11 in V3 (Fig. 2). It is possible that the reversal of
amino acids with the S11R and R/K440S/E substitutionssignificant interaction with either the consensus alanine
at position 19 or after a substitution to valine (4 A˚). represents the maintenance of a direct charge or polar
interaction. This extends the genetic characterizationThese potential interactions provide a possible expla-
nation for the apparent under-representation of the A19V/ carried out by Carrillo and Ratner (1996) using recombi-
nant viral genomes to demonstrate the potential impor-F20V double substitution but they do not explain the link
of these two substitutions to the SI phenotype. To ac- tance of this change in vivo. A physical interaction be-
tween V3 and C4 has been suggested previously basedcount for this it is necessary to extend the model and
propose that the new interaction between A19V and F20 on biochemical approaches (Moore et al., 1993; Wyatt et
al., 1992). It is now necessary to examine the temporaldisrupts a NSI-specific interaction between F20 and
some other portion of the Env protein. The large hy- linkage between changes at this distal position and
changes in V3 during the evolution of SI variants in vivo.drophobic amino acids would substitute for phenylala-
nine for either type of interaction, accounting for their
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